Reading IDXX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IDXX free→Reading IDXX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IDXX free→QuarterlyIQ Insights · IDXX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 5, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the “Separation Date”) and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the “…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the “Company”) notice of her intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) to be held on May 12, 2026. Ms. Szostak’s decision to retire from th…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results,” issued by the Company on February 2, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers CEO Transition. On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the “Transition Date”) and retire from the Company and the Company’s Board of the Directors (the “Board”) immediately…
Entry into a Material Definitive Agreement Amendment No. 2 to Fourth Amended and Restated Credit Agreement On November 12, 2025, IDEXX Laboratories, Inc. (the “ Company ”), with IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., IDEXX Laboratories GmbH, and IDEXX Holdings II GmbH, each a wholly-owned subsidiary (whether directly or indirectly held) of the Company (collectively, the “ Borrowe…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant To the extent required, the information set forth in
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Third Quarter Results,” issued by the Company on November 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORA…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Election of New Director. Effective October 6, 2025, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Karen Peacock as an independent Class I Director and appointed her as a member of its Compensation and Talent Committee and Finance Committee. To effect Ms. Peacock’s election as a Class I Director, the Board…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Second Quarter Results,” issued by the Company on August 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORAT…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Election of New Director. Effective July 10, 2025, the board of directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) elected Joseph L. (Jay) Hooley as an independent Class III Director and appointed him as a member of its Audit Committee and Governance and Corporate Responsibility Committee. To effect Mr. Hooley’s election as a Class…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 1, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIE…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On February 13, 2025, Dr. Asha Collins resigned from the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), effective immediately. Dr. Collins’s decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. The Company and Board t…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results,” issued by the Company on February 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of Nonqualified Deferred Compensation Plan On December 6, 2024, the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), upon the recommendation of the Compensation and Talent Committee of the Board (the “Committee”), approved and adopted the IDEXX Deferred Compensation Plan (the “Plan”). The Plan constitutes an un…
Other Events. On December 3, 2024, the Finance Committee of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) authorized an increase in the Company’s ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company’s common stock. Repurchases may be made at management’s discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in additio…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 20, 2024, Brian P. McKeon, Executive Vice President, Chief Financial Officer and Treasurer of IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) notified the Company that he will retire from IDEXX effective June 1, 2025. Mr. McKeon has served as the Company’s Executive Vice President, Chief Financial Officer and Treasurer since January…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On November 8, 2024, Jonathan W. Ayers, a member of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), resigned from the Board and its finance committee, effective November 8, 2024. A copy of Mr. Ayers’s resignation letter is included as Exhibit 99.1 to this Current Report on Form 8-K. Mr. Ayers’s decision to resig…
Entry into a Material Definitive Agreement. Effective as of October 31, 2024, IDEXX Laboratories, Inc. and certain of its affiliates entered into: (i) an Amendment No. 9 (the “U.S. Amendment”) to the Agreement effective as of October 16, 2003 between IDEXX Operations, Inc. and Ortho-Clinical Diagnostics, Inc. (“Ortho”), as amended by Amendment Nos. 1 to 8 and the Letter Agreement dated July 28, 2023 (the “Original U.S. Supply Agreement” and as amended by the U.S. Amendment, the “U.S. Supply A…
Results of Operations and Financial Condition. On October 31, 2024, the Company filed the Original 8-K, which included the Original Earnings Release. This Amended 8-K replaces the Original Earnings Release with the amended earnings release, which is attached as Exhibit 99.1 to the Amended 8-K (the “Amended Earnings Release”). This Amended Earnings Release corrects and replaces the range of projected 2024 comparable operating profit margin expansion of 70 to 100 basis points set forth in the “…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Third Quarter Results,” issued by the Company on October 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORA…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Second Quarter Results,” issued by the Company on August 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORAT…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory arrangements of Certain Officers. Consulting Agreement with James F. Polewaczyk Effective May 7, 2024, IDEXX Laboratories, Inc. (the “Company”) and James F. Polewaczyk, entered into a Consulting Agreement (the “Consulting Agreement”). Mr. Polewaczyk was an Executive Vice President of the Company who retired effective April 1, 2024. Under this arrangement, Mr. Polewaczyk will provid…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIE…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2023 Results,” issued by the Company on February 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.